Nucleases in homologous recombination as targets for cancer
therapy

J 2014

Nucleases in homologous recombination as targets for cancer therapy

BARTOŠOVÁ, Zdenka a Lumír KREJČÍ

Základní údaje

Originální název

Nucleases in homologous recombination as targets for cancer therapy

Název česky

Nukleázy v homologické rekombinaci jako cíle pro léčbu rakoviny

Autoři

BARTOŠOVÁ, Zdenka (703 Slovensko, domácí) a Lumír KREJČÍ (203 Česká republika, garant, domácí)

Vydání

FEBS Letters, Amsterdam, Elsevier Science, 2014, 0014-5793

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

Genetika a molekulární biologie

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.169

Kód RIV

RIV/00216224:14110/14:00073831

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.febslet.2014.06.010

UT WoS

000339535200013

Klíčová slova česky

Genmická integrita, Homologická rekombinace, Nukleáza, Inhibitor, Léčba rakoviny

Klíčová slova anglicky

Genomic integrity; Homologous recombination; Nuclease; Inhibitor; Cancer therapy

Štítky

EL OK, podil

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 29. 10. 2014 13:47, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Genomic DNA is constantly challenged from endogenous as well as exogenous sources. The DNA damage response (DDR) mechanism has evolved to combat these challenges and ensure genomic integrity. In this review, we will focus on repair of DNA double-strand breaks (DSB) by homologous recombination and the role of several nucleases and other recombination factors as suitable targets for cancer therapy. Their inactivation as well as overexpression have been shown to sensitize cancer cells by increasing toxicity to DNA-damaging agents and radiation or to be responsible for resistance of cancer cells. These factors can also be used in targeted cancer therapy by taking advantage of specific genetic abnormalities of cancer cells that are not present in normal cells and that result in cancer cell lethality. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Návaznosti

GAP207/12/2323, projekt VaV

Název: Endonuleazová a translokázová aktivita v restričních-modifikáčních komplexéch typu I

Investor: Grantová agentura ČR, Endonuleázová a translokázová aktivita v restrikčních-modifikačních komplexech typu I

GA13-26629S, projekt VaV

Název: SUMO a stability genomu

Investor: Grantová agentura ČR, SUMO a stability genomu

Citovat

BARTOŠOVÁ, Zdenka a Lumír KREJČÍ. Nucleases in homologous recombination as targets for cancer therapy. FEBS Letters. Amsterdam: Elsevier Science, 2014, roč. 588, č. 15, s. 2446-2456. ISSN 0014-5793. Dostupné z: https://dx.doi.org/10.1016/j.febslet.2014.06.010.

@article{1196972,
   author = {Bartošová, Zdenka and Krejčí, Lumír},
   article_location = {Amsterdam},
   article_number = {15},
   doi = {http://dx.doi.org/10.1016/j.febslet.2014.06.010},
   keywords = {Genomic integrity; Homologous recombination; Nuclease; Inhibitor; Cancer therapy},
   language = {eng},
   issn = {0014-5793},
   journal = {FEBS Letters},
   title = {Nucleases in homologous recombination as targets for cancer therapy},
   volume = {588},
   year = {2014}
}

TY  - JOUR
ID  - 1196972
AU  - Bartošová, Zdenka - Krejčí, Lumír
PY  - 2014
TI  - Nucleases in homologous recombination as targets for cancer therapy
JF  - FEBS Letters
VL  - 588
IS  - 15
SP  - 2446-2456
EP  - 2446-2456
PB  - Elsevier Science
SN  - 00145793
KW  - Genomic integrity
KW  - Homologous recombination
KW  - Nuclease
KW  - Inhibitor
KW  - Cancer therapy
N2  - Genomic DNA is constantly challenged from endogenous as well as exogenous sources. The DNA damage response (DDR) mechanism has evolved to combat these challenges and ensure genomic integrity. In this review, we will focus on repair of DNA double-strand breaks (DSB) by homologous recombination and the role of several nucleases and other recombination factors as suitable targets for cancer therapy. Their inactivation as well as overexpression have been shown to sensitize cancer cells by increasing toxicity to DNA-damaging agents and radiation or to be responsible for resistance of cancer cells. These factors can also be used in targeted cancer therapy by taking advantage of specific genetic abnormalities of cancer cells that are not present in normal cells and that result in cancer cell lethality. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
ER  -

BARTOŠOVÁ, Zdenka a Lumír KREJČÍ. Nucleases in homologous recombination as targets for cancer therapy. \textit{FEBS Letters}. Amsterdam: Elsevier Science, 2014, roč.~588, č.~15, s.~2446-2456. ISSN~0014-5793. Dostupné z: https://dx.doi.org/10.1016/j.febslet.2014.06.010.

Podrobný výpis o publikaci